Serum PSA as a tumor marker for patients undergoing definitive radiation therapy.
This article summarizes the clinical utility of PSA both as pretreatment prognostic factor and as an invaluable post-treatment marker. Some pathobiologic correlations between serum PSA kinetics and putative tumor cell kinetic mechanisms are discussed.